`
`EXHIBIT 14
`TO THE DECLARATION OF BRIAN J.
`NISBET IN SUPPORT OF
`DEFENDANTS’ MOTIONS IN LIMINE
`
`
`
`Case 3:18-cv-00347-CAB-MDD Document 358-1 Filed 11/19/21 PageID.33938 Page 2 of 9
`
`1 UNITED STATES DISTRICT COURT
` SOUTHERN DISTRICT OF CALIFORNIA
`2 SAN DIEGO DIVISION
`
`3 4
`
` NUVASIVE, INC., a Delaware )
` corporation, )
`5 )
` Plaintiff, )
`6 )
` vs. ) Case No.
`7 ) 3:18-CV-00347-
` ALPHATEC HOLDINGS, INC., a ) CAB-MDD
`8 Delaware corporation and )
` ALPHATEC SPINE, INC., a )
`9 California corporation, )
` )
`10 Defendants. )
` __________________________________)
`11
`
`12
`
`13 HIGHLY CONFIDENTIAL - ATTORNEY'S EYES ONLY
`
`14 VIDEOTAPED DEPOSITION OF
`
`15 NUVASIVE, INC.
`
`16 GREGORY LUCIER
`
`17
`
`18 January 17, 2020
`
`19 9:06 a.m.
`
`20
`
`21 3580 Carmel Mountain Road, Suite 300
`
`22 San Diego, California
`
`23
`
`24 Lorie Rhyne, CSR No. 12905
`
`25
`
`EXHIBIT 14 - PAGE 307
`
`
`
`Case 3:18-cv-00347-CAB-MDD Document 358-1 Filed 11/19/21 PageID.33939 Page 3 of 9
`
`Page 2
`
`1 APPEARANCES OF COUNSEL
`
` On Behalf of the Plaintiff:
`
`2 3
`
`4 PAUL D. TRIPODI II, ESQ.
`
`5 Wilson Sonsini Goodrich & Rosati P.C.
`
`6 633 West Fifth Street, Suite 1550
`
`7 Los Angeles, California 90071
`
`8 (323) 210-2900
`
`9 ptripodi@wsgr.com
`
`10
`
`11 On Behalf of the Defendants:
`
`12 NIMALKA R. WICKRAMASEKERA, ESQ.
`
`13 Winston & Strawn LLP
`
`14 333 South Grand Avenue, Suite 3800
`
`15 Los Angeles, California 90071-1543
`
`16 (213) 615-1700
`
`17 nwickramasekera@winston.com
`
`18
`
`19 Videographer: GIANNI ORTIZ
`
`20 Also Present: MICHAEL DOYLE, in-house counsel,
`
`21 NuVasive
`
`22 CRAIG HUNSAKER, Executive Vice
`
`23 President and General Counsel
`
`24 at Alphatec Spine
`
`25 TYSON MARSHALL, Associate General
` Counsel, Alphatec Spine
`
`EXHIBIT 14 - PAGE 308
`
`
`
`Case 3:18-cv-00347-CAB-MDD Document 358-1 Filed 11/19/21 PageID.33940 Page 4 of 9
`
`·1· · · · · · · · · · · INDEX OF EXAMINATION
`
`·2· ·WITNESS:· GREGORY LUCIER
`
`Page 3
`
`·3· ·EXAMINATION· · · · · · · · · · · · · · · · · PAGE
`
`·4· ·By Ms. Wickramasekera· · · · · · · · · · · · · 5
`
`·5
`
`·6· · · · · · · · · · · ·INDEX TO EXHIBITS
`
`·7· ·DEFENDANTS· DESCRIPTION· · · · · · · · · · · PAGE
`
`·8· ·Exhibit 1· ·E-mail dated 9/8/2016,
`
`·9· · · · · · · ·NUVA_ATEC0318999· · · · · · · · ·145
`
`10· ·Exhibit 2· ·Letter dated September 8, 2016,
`
`11· · · · · · · ·NUVA_ATEC0319003 to
`
`12· · · · · · · ·NUVA_ATEC0319004· · · · · · · · ·149
`
`13· ·Exhibit 3· ·E-mail dated 9/7/2016, NUVA_ATEC0332186
`
`14· · · · · · · ·to NUVA_ATEC0332187· · · · · · · 156
`
`15· ·Exhibit 4· ·Project Titan, Management Presentation
`
`16· · · · · · · ·for NuVasive, NUVA_ATEC0319062· ·205
`
`17· ·Exhibit 5· ·Management Presentation, Alphatec Spine,
`
`18· · · · · · · ·A Leading Provider of Advanced
`
`19· · · · · · · ·Spinal Fusion Platforms and Systems,
`
`20· · · · · · · ·NUVA_LLIF000854436 to
`
`21· · · · · · · ·NUVA_LLIF000854524· · · · · · · ·205
`
`22· ·Exhibit 6· ·E-mail dated 10/1/2017,
`
`23· · · · · · · ·NUVA_ATEC0318549· · · · · · · · ·245
`
`24· ·Exhibit 7· ·E-mail dated 10/2/2017,
`
`25· · · · · · · ·NUVA_ATEC0318492· · · · · · · · ·263
`
`EXHIBIT 14 - PAGE 309
`
`
`
`Case 3:18-cv-00347-CAB-MDD Document 358-1 Filed 11/19/21 PageID.33941 Page 5 of 9
`
`Page 303
`
` REDACTED
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`BY MS. WICKRAMASEKERA:
`
`Q.
`
`A.
`
`What is Paul McClintock's role?
`
`Paul McClintock's role currently is head of
`
`Western United States, sales and marketing.
`
`Q.
`
`A.
`
`Q.
`
`A.
`
`Were his duties recently changed?
`
`They were recently changed.
`
`Why?
`
`That was a decision by the current CEO to
`
`restructure the us sales force structure.
`
`Q.
`
`Did you tell the NuVasive directors and
`
`16
`
`officers at a leadership retreat in Palm Springs that
`
`17
`
`18
`
`19
`
`20
`
`you took the NuVasive spine exam?
`
`A.
`
`I don't recall saying that.
`
`I did not take
`
`the NuVasive spine exam.
`
`Q.
`
`Are you aware that the patent office is
`
`21
`
`considering invalidating several of NuVasive•s implant
`
`22
`
`patents at issue in this matter?
`
`23
`
`24
`
`25
`
`A.
`
`Q.
`
`A.
`
`I'm not aware of that.
`
`Nobody told you that?
`
`I'm not aware of the details at that level.
`
`EXHIBIT 14 - PAGE 310
`
`
`
`Case 3:18-cv-00347-CAB-MDD Document 358-1 Filed 11/19/21 PageID.33942 Page 6 of 9
`
`Page 304
`1 Q. Are you aware that if NuVasive is found to
`
`2 have brought a suit for an improper purpose, Alphatec
`
`3 will have an actionable claim against NuVasive for its
`
`4 legal fees?
`
`5 MR. TRIPODI: Objection to the extent it
`
`6 calls for a legal conclusion. Lack of foundation.
`
`7 THE WITNESS: Those are legal conclusions
`
`8 I'm not willing to --
`
`9 (Reporter clarification.)
`
`10 MR. TRIPODI: Lack of foundation. Calls for
`
`11 a legal conclusion.
`
`12 THE COURT REPORTER: Answer?
`
`13 THE WITNESS: That sounds like a legal
`
`14 detail, legal matter involving lawyers, and I'm not
`
`15 going to answer the question.
`
`16 BY MS. WICKRAMASEKERA:
`
`17 Q. Would that have been an important factor in
`
`18 the calculus as to whether to bring the lawsuits
`
`19 regarding the fact that if you lose some of these
`
`20 lawsuits, you may have to pay Alphatec millions of
`
`21 dollars in legal fees?
`
`22 MR. TRIPODI: Same objection.
`
`23 THE WITNESS: I'll follow the advice of
`
`24 counsel.
`
`25 MS. WICKRAMASEKERA: What was your -- what's
`
`EXHIBIT 14 - PAGE 311
`
`
`
`Case 3:18-cv-00347-CAB-MDD Document 358-1 Filed 11/19/21 PageID.33943 Page 7 of 9
`
`EXHIBIT 14 - PAGE 312
`
`
`
`Case 3:18-cv-00347-CAB-MDD Document 358-1 Filed 11/19/21 PageID.33944 Page 8 of 9
`
`EXHIBIT 14 - PAGE 313
`
`
`
`Case 3:18-cv-00347-CAB-MDD Document 358-1 Filed 11/19/21 PageID.33945 Page 9 of 9
`
`EXHIBIT 14 - PAGE 314
`
`